Amicus Therapeutics (FOLD) Receives Daily Media Sentiment Score of 0.22

Media coverage about Amicus Therapeutics (NASDAQ:FOLD) has trended somewhat positive recently, Accern Sentiment reports. Accern identifies positive and negative media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Amicus Therapeutics earned a news sentiment score of 0.22 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 45.4575777487344 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

These are some of the news headlines that may have impacted Accern’s scoring:

Amicus Therapeutics (NASDAQ:FOLD) opened at $15.68 on Thursday. The company has a market cap of $2,610.00, a P/E ratio of -8.57 and a beta of 1.45. Amicus Therapeutics has a 12 month low of $5.87 and a 12 month high of $17.40. The company has a debt-to-equity ratio of 0.39, a quick ratio of 6.22 and a current ratio of 6.32.

Several equities analysts have recently weighed in on the stock. Zacks Investment Research downgraded shares of Amicus Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, December 19th. BidaskClub downgraded shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday. Robert W. Baird set a $20.00 target price on shares of Amicus Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, February 7th. Cowen reiterated a “buy” rating and issued a $22.00 target price on shares of Amicus Therapeutics in a research note on Wednesday, January 10th. Finally, Leerink Swann lifted their target price on shares of Amicus Therapeutics from $20.00 to $24.00 and gave the stock an “outperform” rating in a research note on Thursday, February 8th. Four analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Amicus Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $19.06.

In related news, CEO John F. Crowley sold 47,213 shares of the business’s stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $13.61, for a total transaction of $642,568.93. Following the completion of the transaction, the chief executive officer now owns 375,214 shares of the company’s stock, valued at $5,106,662.54. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO John F. Crowley sold 65,581 shares of the business’s stock in a transaction that occurred on Thursday, December 21st. The shares were sold at an average price of $13.51, for a total transaction of $885,999.31. Following the transaction, the chief executive officer now directly owns 393,076 shares of the company’s stock, valued at approximately $5,310,456.76. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 250,390 shares of company stock valued at $3,620,581. 3.40% of the stock is owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: “Amicus Therapeutics (FOLD) Receives Daily Media Sentiment Score of 0.22” was first posted by Markets Daily and is the sole property of of Markets Daily. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://www.themarketsdaily.com/2018/02/15/amicus-therapeutics-fold-receives-daily-media-sentiment-score-of-0-22.html.

About Amicus Therapeutics

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Insider Buying and Selling by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply